We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Coloplast AS | TG:CBHD | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.18% | 110.80 | 110.50 | 111.05 | 111.05 | 107.65 | 111.05 | 1,775 | 22:50:06 |
Announcement of Full-year Financial Results 2022/23(1 October 2022 - 30 September 2023)
Coloplast delivered Q4 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 3% to 6,226 million, impacted by unfavourable development in currencies
FY 2022/23 organic growth of 8% and 28% EBIT margin1). Reported revenue in DKK grew 9% to DKK 24,500 million
Acquisition of Kerecis finalised on 31 August 20233)
FY 2023/24 financial guidance – organic revenue growth of around 8% and an EBIT margin of 27-28%
“We deliver a solid set of numbers in 2022/23 with 8% organic growth and an EBIT margin of 28%, in line with our financial guidance. We continue to take market share across all our business areas and maintain an industry-leading profitability level. I would like to highlight our strong performance in Chronic Care, where we continue to deliver high-single digit growth despite the negative impact on our ostomy business in China from Covid-19. This year, we also made good progress on innovation and launched our new intermittent catheter Luja™. Finally, in Q4 we completed the acquisition of Kerecis, an emerging category leader in the biologics wound care segment. With our strong core of businesses and the assets added to our portfolio through acquisitions in recent years, I look forward to accelerating our long-term growth to 8-10%, while maintaining a long-term EBIT margin of above 30%,” says Kristian Villumsen, President and CEO of Coloplast.
Conference call
Coloplast will host a conference call on Thursday, 9 November 2023 at 11.00 CET. The call is expected to last about one hour.To actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register hereAccess the conference call webcast directly here: FY 22/23 conference call
1) Before special items of DKK 69 million in Q4 2022/23 and before special items of DKK 74 million in FY 2022/23. 2) Before special items of DKK 36 million in Q4 2021/22 and DKK 471 million in FY 2021/22. 3) The terms of the transaction and the financial assumptions stated in Coloplast's stock exchange announcement no. 03/2023 regarding the acquisition of Kerecis are unchanged and can be found here: Acquisition of Kerecis
For further information, please contact
Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111
Aleksandra DimovskaSenior Director, Investor RelationsTel. +45 4911 1800 / +45 4911 2458Email: dkadim@coloplast.com
Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266Email: dkkhu@coloplast.com
Press and mediaPeter MønsterSr. Media Relations ManagerTel. +45 4911 2623Email: dkpete@coloplast.com
AddressColoplast A/SHoltedam 1DK-3050 HumlebaekDenmarkCompany reg. (CVR) no. 69749917
Websitewww.coloplast.com
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.
Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound and Skin Care, Interventional Urology and Voice and Respiratory Care.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2023-11.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
Attachment
1 Year Coloplast AS Chart |
1 Month Coloplast AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions